The average target price of MLYS is 39 and suggests 181% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase one's position in this instrument in the next 12 months. The most optimistic analyst has a target price of 48.0. This translates into 250% upside potential in the best case. On the other hand, the most pessimistic analyst has a target price of 15.0. This suggests 9% upside potential. Even the most pessimistic analyst believes there will be stock growth. 

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Mineralys Therapeutics, Inc.

Healthcare

The company does not pay dividends at all, or it pays them sporadically. There have only been a few years with dividend payments in the past ten years. 

MLYS reported revenue of USD 0mn in the last 12 months, down 0% from FY24. The dynamics of cash flow, as measure by free cash flow (FCF), were rather similar. EPS grew 2% from FY24 to USD -3.73.

Over the last six months, the stock performance has varied, with an increase following a drop. The stock's price trend wasn't definitive when matched against its global counterparts from the same sector and industry (as depicted above). Over the past six months the stock has exceeded the performance of this peer group by 13ppts and its growth decelerated by 14ppts in the past month. This is equally valid for peers from the same country and industry. Given the stock's valuation versus its peers, its total price movement is neither favourable nor unfavourable.

Mineralys Therapeutics, Inc. reported a return on equity (RoE) of -64.7% in the last 12 months, up from -76.1% in FY23. The market consensus projects an RoE of -48.6% in FY24, again behind its peers. 

Another important profitability metric, return on assets (RoA), amounted to -62.2% in the last 12 months, a decrease from -39.3% in FY23. The market analysts predict that RoA will be -46.6% in FY24, again weaker than its peers. 

In the last 12 months, the return on capital employed (RoCE) declined to -64.7%, below the peers. 

The ratio of return on invested capital (RoIC) to the weighted average cost of capital (WACC) has been -3.4 in the past several years. This ratio implies a fragile shareholder value creation. 

The institutional, legal, and compliance risks associated with the company's country are minimal. In combination with stringent business standards, shareholder rights are very highly protected.

MLYS has below average trading liquidity. The average private investor can sell his common position in the stock almost immediately. Liquidity is very unstable and is somewhat unfavourable on the days with the lowest activity. The trading volume mostly stays the same even under highly turbulent market conditions. The stock has a small market capitalisation, which usually makes its trading liquidity erratic and unpredictable. 

No other major risks have been identified.

The risk of default is very high. Among the negative credit factors and we point to negligible return on capital, inadequate interest coverage.

In highly turbulent market conditions, MLYS is exceptionally volatile. In other words, the stock will be among the worst-performers in times of extreme market volatility or shocking company news. Standalone, the worst-day losses (less than 1% of the time) will likely be critical. 

In normal market circumstances, MLYS is exceptionally volatile. Put differently, without outstanding market volatility or shocking company news, the stock's price will change quite unpredictably. The stock's losses on its worst days (less than 1-5% of the time) will range from critical to immense. 

From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. 

Mineralys Therapeutics, Inc.

$ 13.7

2

Mineralys Therapeutics, Inc.

$ 13.7

2

Risk factor

Profitability factor

Risk / Profitability

Risk factor

Profitability factor

$ 13.7

About

About

About

About